Paricalcitol Has a Potent Anti-Inflammatory Effect in Rat Endothelial Denudation-Induced Intimal Hyperplasia

Area of Science:

• Vascular Biology
• Pharmacology

Background:

• Neointimal hyperplasia is a primary cause of vascular graft failure.
• Vitamin D receptor (VDR) activation influences vascular smooth muscle cells and may protect against neointimal hyperplasia.
• The precise molecular mechanisms of VDR action in this context remain unclear.

Purpose of the Study:

• To investigate the impact of paricalcitol, a selective VDR activator, on neointimal hyperplasia following guidewire-induced endothelial injury in rats.
• To assess paricalcitol's effect on the expression of key cellular stress factors in injured arteries.

Main Methods:

• Rats underwent guidewire-induced endothelial injury.
• Paricalcitol or vehicle was administered.
• Neointimal hyperplasia and luminal stenosis were evaluated.
• mRNA expression of growth/differentiation factor-15 (GDF-15), CD74, NFκB-inducing kinase (NIK), and monocyte chemoattractant protein-1 (MCP-1/CCL2) was assessed via RT-PCR.
• Immunohistochemistry was used to confirm protein expression of CD74 and NIK.

Main Results:

• Guidewire injury induced neointimal hyperplasia, luminal stenosis, and upregulated GDF-15, CD74, NIK, and MCP-1/CCL2 expression.
• Paricalcitol treatment did not significantly alter neointimal hyperplasia or luminal stenosis.
• Paricalcitol significantly reduced the expression of GDF-15, CD74, NIK, and MCP-1/CCL2 mRNA to levels seen in control arteries.

Conclusions:

• Paricalcitol effectively suppressed the cellular stress response to endothelial injury in rat arteries.
• Despite reducing stress markers, paricalcitol had a limited impact on neointimal hyperplasia and luminal stenosis.
• This study identifies novel molecular targets of paricalcitol within the vascular system, independent of direct tissue repair effects.